All In MedTech

Device Trial Radar · NCT07873892

Transarterial Embolization Versus Sham Procedure in Adults With Treatment-Resistant Inflammatory Arthritis of a Single Large Joint

Advancing Discoveries in Vascular Embolization for New Treatments in Rheumatology: a Single-blind, Sham-controlled, Randomized Trial

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Istituto Ortopedico RizzoliAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AUSL Bologna
First posted
Oct 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether transarterial embolization (TAE) can relieve pain and improve well-being in adults with inflammatory arthritis that remains active in only one large joint (wrist, elbow, shoulder, ankle, knee or hip) despite anti-inflammatory drugs, joint injections and physiotherapy. The researchers expect that more people treated with TAE than with a sham (simulated) procedure will reach low pain and a good overall assessment of their health one month after the procedure. The main questions it aims to answer are: * Does TAE increase the proportion of participants who reach low pain and a good overall assessment of their health one month after the procedure, compared with a sham procedure? * Is TAE safe, and does it improve quality of life and reduce the need for medication over three months? TAE is a minimally invasive procedure. A thin catheter is guided through an artery in the groin or wrist to the small vessels that feed the inflamed lining of the joint, and tiny resorbable gelatin particles are injected to temporarily reduce the abnormal blood flow that sustains inflammation and pain. Researchers will compare TAE with a sham procedure to find out whether any benefit comes from the embolization itself rather than from the experience of undergoing a procedure. Participants will: * Be randomly assigned (like flipping a coin) to TAE or to the sham procedure. Neither the participants nor the doctor who evaluates them will know which procedure they received. * Undergo the procedure in the angiography room with light sedation. The sham procedure takes place in the same room, with the same team, sedation and duration, but without any puncture of the artery, contrast medium or X-rays. * Attend visits before the procedure and 1 week, 1 month and 3 months after it, answer questionnaires on pain and quality of life, and keep a diary of symptoms and medicines for 7 days after the procedure. After 3 months, participants who received the sham procedure will be offered TAE.

Conditions

  • Arthritis

Interventions

  • Transarterial embolization with resorbable gelatin microspheresDevice

    Superselective transarterial embolization of the arteries supplying the inflamed synovium of the target joint, using resorbable porcine gelatin microspheres (100-300 micrometres; CE-marked class III device) injected through a coaxial microcatheter until the pathological blush disappears. Ultrasound-guided femoral or radial access, light sedation with midazolam 2 mg IV and local anaesthesia. Single procedure.

  • Sham embolization procedureDevice

    Simulated embolization procedure in the angiography suite with identical sedation (midazolam 2 mg IV), local anaesthesia and duration as the active procedure. Superficial subcutaneous puncture at the access site without arterial access, saline infusion and display of standardized angiographic sequences. No contrast medium, embolic agent or ionizing radiation. Single procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with pain VAS ≤15 mm and Patient Global Assessment ≤20 mm.Time frame: 1 month after the procedure.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.